Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 13 January 2026 - 20 January 2026

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

Microsoft stock dips after-hours as Bristol Myers AI lung-cancer deal lands and tariff jitters shake tech

New York, January 20, 2026, 16:33 (EST) — After-hours trading underway. Shares of Microsoft Corp dipped 1.1% to $454.52 in after-hours trading Tuesday, moving between $449.06 and $456.76 during the session. The software giant’s market cap stands near $3.85 trillion. The stock fell amid a tough session for risk assets, as trade news and rate concerns drove investors away from popular growth stocks. Microsoft, often seen as a gauge for enterprise tech spending, typically tracks these shifts closely. Timing complicates things. As earnings season nears, even routine company updates can spark a sharper market move—or be dismissed altogether—based on what
20 January 2026
······
Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

Novo Nordisk Class B stock jumps — Wegovy pill scripts and UK dose nod set up the week ahead

COPENHAGEN, Jan 18, 2026, 21:16 CET — Market closed. Novo Nordisk A/S Class B shares (NOVOb.CO) surged 6.49% on Friday, closing at 388.9 Danish crowns after hitting a high of 391.3 crowns during the session. The stock is set to reopen Monday, with traders reacting to the latest Wegovy news. (Investing.com) Investors are weighing whether Novo’s once-daily Wegovy pill is gaining traction in the U.S. as the obesity drug market shifts toward a consumer-driven, cash-pay model. IQVIA data revealed 3,071 retail prescriptions filled within the first four days after its Jan. 5 launch. Novo described the “early signs” as positive
18 January 2026
·······
Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

Healthcare stocks slide into long weekend as XLV drops; J&J earnings loom

NEW YORK, January 17, 2026, 14:16 EST — The market has closed. U.S. healthcare stocks wrapped up the week as the S&P 500’s weakest sector, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.8% on Friday to $155.74. Anthony Saglimbene, chief market strategist at Ameriprise Financial, noted that “most investors will take that as a win,” given the market hovered near record highs despite a volatile week. (Reuters) U.S. markets are closed Monday for Martin Luther King Jr. Day, giving healthcare investors an extended break before action resumes Tuesday. The sector has fallen behind despite earnings season picking
17 January 2026
··········
UnitedHealth stock price falls into holiday-short week as Trump health plan raises stakes for UNH earnings

UnitedHealth stock price falls into holiday-short week as Trump health plan raises stakes for UNH earnings

New York, Jan 17, 2026, 11:58 (EST) — Market closed Shares of UnitedHealth Group Incorporated dropped 2.3% on Friday, closing at $331.02 and capping off a weaker week. Trading volume hit roughly 8.0 million shares, with the stock fluctuating between $330.49 and $339.00 during the session. Markets in the U.S. will remain closed Monday for Martin Luther King Jr. Day, delaying the next trading session. Stocks are set to resume action on Tuesday, marking a brief week ahead. (New York Stock Exchange) Timing is crucial. UnitedHealth, a key player in managed care, also operates a major pharmacy benefit manager (PBM)
17 January 2026
····
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Copenhagen, Jan 17, 2026, 10:59 CET — Market closed. Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33. (Investing.com) This move is crucial as investors seek confirmation that Novo’s new Wegovy pill will maintain its first-to-market advantage amid growing competition, notably from Eli Lilly’s oral obesity drug. Novo described the “early signs” as positive but cautioned that it’s too soon to draw conclusions about trends for the daily pill. (Reuters) The initial figure was modest but clear:
17 January 2026
·······
Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

New York, Jan 15, 2026, 19:27 EST — After-hours Johnson & Johnson shares (JNJ.N) rose about 0.5% in after-hours trading on Thursday to $219.57, after swinging between $215.93 and $219.73 during the regular session. The healthcare conglomerate is set to report fourth-quarter results on Jan. 21, with Chief Executive Joaquin Duato and Chief Financial Officer Joseph Wolk scheduled to lead an 8:30 a.m. ET conference call. Guidance for 2026 is likely to do most of the work on the day. (JNJ.com) Late on Wednesday, the company said its Phase 3 MajesTEC-9 study of Tecvayli (teclistamab) showed a 71% reduction in
16 January 2026
·····
UnitedHealth stock climbs as UnitedHealthcare rolls out fast-pay Medicare Advantage pilot for rural hospitals

UnitedHealth stock climbs as UnitedHealthcare rolls out fast-pay Medicare Advantage pilot for rural hospitals

NEW YORK, Jan 15, 2026, 18:09 EST — After-hours Shares of UnitedHealth Group Incorporated climbed $3.95, or 1.2%, to close at $338.96 on Thursday, beating the modest gains seen across the broader market. Attention turned back to the company’s government-backed insurance segment, where shifts in payment schedules, medical expenses, and policy changes can quickly alter market sentiment. UnitedHealthcare on Wednesday kicked off a six-month pilot to speed up Medicare Advantage payments for select independent rural hospitals in Oklahoma, Idaho, Minnesota, and Missouri. The goal: slash collection times to less than 15 days, down from under 30. The move comes as
16 January 2026
···
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

New York, Jan 15, 2026, 18:09 (ET) — After-hours update. Shares of Boston Scientific Corp (NYSE: BSX) dropped roughly 4% Thursday following its deal to acquire blood-clot treatment company Penumbra. Boston Scientific’s stock slipped $3.75, closing near $90.03 in late U.S. trading. Meanwhile, Penumbra (NYSE: PEN) surged around 12%, reaching $350.49. Boston Scientific announced it will pay $374 per Penumbra share in a mix of cash and stock, putting the deal’s value at about $14.5 billion. CEO Mike Mahoney described the acquisition as a chance to break into fast-growing vascular segments, leveraging Penumbra’s mechanical thrombectomy catheters—devices designed to remove blood
16 January 2026
·····
Penumbra (PEN) stock slides 5% after CEO flags manufacturing shift at JPM conference

Penumbra (PEN) stock slides 5% after CEO flags manufacturing shift at JPM conference

New York, Jan 13, 2026, 15:57 EST — Regular session Penumbra (NYSE: PEN) shares dropped Tuesday following comments from CEO Adam Elsesser about shifting the company’s manufacturing base. The stock slid 5.2% to $302.70 in late trading after hitting a low of $290.42 earlier. Elsesser told a conference that “All of our products today are manufactured in California. That’s going to change.” (Seeking Alpha) The comment came as investors digested new insights from the J.P. Morgan Healthcare Conference in San Francisco, an annual event where executives typically lay out their vision for the coming year. For a stock trading close
13 January 2026
····
Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

Arcus Biosciences stock jumps on Goldman upgrade as traders eye JPM Healthcare stage

New York, Jan 13, 2026, 13:22 (EST) — Regular session Arcus Biosciences shares rose nearly 5% on Tuesday after Goldman Sachs upgraded the biotech to “Buy” and lifted its price target. The stock was up 4.8% at $22.32 in early afternoon trading. (TipRanks) The call hit in the middle of the J.P. Morgan Healthcare Conference week, when investors often press small and mid-cap biotechs for timelines and trial updates. Arcus is due to present on Wednesday. (Arcus Biosciences) Goldman’s analyst Richard Law pointed to Arcus’s lead program, casdatifan, a HIF-2α inhibitor in development for advanced clear cell renal cell carcinoma,
13 January 2026
·····
Kaiser’s $46 million privacy settlement is live — here’s how to file a claim before March 12

Kaiser’s $46 million privacy settlement is live — here’s how to file a claim before March 12

San Francisco, January 13, 2026, 04:18 PST Kaiser Permanente started sending settlement notices this week after a federal court gave the green light to a $46 million class action settlement. The case involves alleged patient data leaks linked to its websites and mobile apps. Members eligible for compensation must submit claims by March 12 to qualify for a payout, the notice says. https://www.cbsnews.com/sanfrancisco/news/kaiser-permanante-settlement-file-claim-46-million-privacy-patient-data/ The timing is crucial as healthcare groups face lawsuits over “tracking pixels” and similar tech — tiny snippets of code designed to monitor site traffic and target ads. Patients claim these tools secretly shared their data with
13 January 2026
····
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

New York, Jan 12, 2026, 19:48 EST — After-hours AbbVie shares barely moved in after-hours Monday following a new three-year pricing pact with the Trump administration. The drugmaker also announced two deals to strengthen its pipeline and boost U.S. manufacturing. The stock slipped less than 0.1% to $220.04. The timing is crucial as Washington ramps up pressure on drugmakers over pricing, while trade policy and tariffs linger in corporate discussions. Investors are sorting out which costs are truly significant versus just noise. AbbVie’s moves bring policy risk, dealmaking, and capital spending into one sharp focus. With earnings season approaching for
13 January 2026
·····
1 2 3 4 5 6 … 13

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop